Studies on the Formation and Inactivation of Human Blood Coagulation Product I^[*]

Summary

Although thrombin formed in product I generating mixtures, product I and thrombin activity were essentially uncorrelated. The addition of thrombin to generating mixtures caused acceleration of product I formation, but failed to elicit product I formation in “incomplete” systems. Product I was found to be relatively stable when formed with diluted reagents or separated from certain plasma proteins. When inactivation occurred with concentrated reagents, activity was restored only with further addition of reagents containing AHF. The stability of product I at 57° C is similar to that of AHF. When product I is reacted with a source of phosphatide to form blood thromboplastin, little product I “consumption” occurs.

• References

• 1 Biggs R, Douglas A. S, Macfarlane R. G. The formation of thromboplastin in human blood. J. Physiol. 111: 89 1953;
• 2 Bergsagel D. E. Studies on the formation of blood thromboplastin. Ph. D. Thesis. University of Oxford; June, 1955
• 3 Hougie C. The role of factor V in the formation of blood thromboplastin. J. Lab. clin. Med. 50: 61 1957;
• 4 Horowitz H. I. Unpublished observations.
• 5 Horowitz H. I, Spaet T. H. The generation of coagulation product I and its interaction with platelets and phospholipids. J. appl. Physiol. 16: 112 1961;
• 6 Fisch U, Duckert F. Some aspects of kinetics of the first stages of blood thromboplastin formation. Thromb. Diath. haem. 03: 98 1959;
• 7 Spaet T. H, Cintron J. Clearance of blood coagulation product I in rabbits. Proc. Soc. exp. Biol. (N. Y.) 104: 498 1960;
• 8 Zucker-Franklin D, Javid J, Spaet T. H. Characterization of blood coagulation product I. Fed. Proc. 20: 53 1961;
• 9 Spaet T. H, Garner E. S. Inactivation of thromboplastin in human blood. J. clin. Invest. 34: 1807 1955;
• 10 Deutsch E, Mammen E. The inactivation of plasma-thromboplastin. Thromb. Diath. haem. 02: 324 1958;
• 11 Ratnoff O. D, Calopy J. E. A familial hemorrhagic trait associated with a deficiency of a clot-promoting factor of plasma. J. clin. Invest. 34: 602 1955;
• 12 Lewis J. H, Soulier J. P, Taylor F. H. L. Chemical, clinical, and immunological studies on the products of human plasma fractionation. XXXIII. The coagulation defect in hemophilia: The effect in vitro and in vivo on the coagulation time in hemophilia of a prothrombin and fibrinogen-free normal plasma and its derived protein fraction. J. clin. Invest. 25: 876 1946;
• 13 Bergsagel D. E, Hougie C. Intermediate stages in the formation of blood thromboplastin. Brit. J. Haemat. 02: 113 1956;
• 14 Spaet T. H, Cintron J. Blood thromboplastin: its preparations and properties. Proc. Soc. exp. Biol. (N. Y.) 101: 799 1959;
• 15 Spaet T. H. Umpublished observations.
• 16 Lever W. F, Gurd F. R. N, Uroma E, Brown R. K, Barnes B. A, Schmid K, Schultz E. L. Chemical, clinical, and immunological studies on the products of human plasma fractionation. XL. Quantitative separation and determination of the protein components in small amounts of normal human plasma. J. clin. Invest. 30: 99 1951;
• 17 Wessler S, Reiner L, Freiman D. G, Reimer S. M, Lertzman M. Serum-induced thrombosis. Studies of its induction and evolution under controlled conditions in vivo. Circulation. 20: 864 1959;